Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eveline A M Heijnsdijk

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health IndexEveline A M Heijnsdijk, Dwight Denham, Harry J de Koning
Scientific Reports|January 20, 2021
The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling studyAbraham M Getaneh, Eveline A M Heijnsdijk, Harry J de Koning
The Prostate|April 19, 2017
When should active surveillance for prostate cancer stop if no progression is detected?Tiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
International Journal of Cancer|December 24, 2015
Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) menTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
International Journal of Cancer|August 16, 2014
Screening for prostate cancer in the US? Reduce the harms and keep the benefitTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
BJU International|May 26, 2016
Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation studyTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
Cancer|December 13, 2017
Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillanceTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 17, 2011
How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screeningElisabeth M Wever, Gerrit Draisma, Eveline A M Heijnsdijk, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 11, 2019
Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using EmulatorsTiago M de Carvalho, Eveline A M Heijnsdijk, Luc Coffeng, et al.
Cancer Medicine|August 20, 2020
Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenariosAbraham M Getaneh, Eveline A M Heijnsdijk, Monique J Roobol, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health IndexEveline A M Heijnsdijk, Dwight Denham, Harry J de Koning
Scientific Reports|January 20, 2021
The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling studyAbraham M Getaneh, Eveline A M Heijnsdijk, Harry J de Koning
The Prostate|April 19, 2017
When should active surveillance for prostate cancer stop if no progression is detected?Tiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
International Journal of Cancer|December 24, 2015
Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) menTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
International Journal of Cancer|August 16, 2014
Screening for prostate cancer in the US? Reduce the harms and keep the benefitTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
BJU International|May 26, 2016
Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation studyTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
Cancer|December 13, 2017
Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillanceTiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 17, 2011
How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screeningElisabeth M Wever, Gerrit Draisma, Eveline A M Heijnsdijk, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 11, 2019
Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using EmulatorsTiago M de Carvalho, Eveline A M Heijnsdijk, Luc Coffeng, et al.
Cancer Medicine|August 20, 2020
Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenariosAbraham M Getaneh, Eveline A M Heijnsdijk, Monique J Roobol, et al.
Pageof 8